Getting personal: Endogenous adenosine receptor signaling in lymphoblastoid cell lines

Overington, 2006, How many drug targets are there?, Nat. Rev. Drug Discov., 5, 993, 10.1038/nrd2199 Russ, 2005, The druggable genome: an update, Drug Discov. Today, 10, 1607, 10.1016/S1359-6446(05)03666-4 Fredholm, 2011, International union of basic and clinical pharmacology. LXXXI. Nomenclature and classification of adenosine receptors – an update, Pharmacol. Rev., 63, 1, 10.1124/pr.110.003285 Jacobson, 2006, Adenosine receptors as therapeutic targets, Nat. Rev. Drug Discov., 5, 247, 10.1038/nrd1983 Muller, 2015, The safety of istradefylline for the treatment of Parkinson’s disease, Expert Opin. Drug Saf., 1–7 Venkatakrishnan, 2013, Molecular signatures of G-protein-coupled receptors, Nature, 494, 185, 10.1038/nature11896 Davies, 2006, Pharmacologic analysis of non-synonymous coding h5-HT2A SNPs reveals alterations in atypical antipsychotic and agonist efficacies, Pharmacogenomics J., 6, 42, 10.1038/sj.tpj.6500342 Docherty, 2012, A genetic association study of DNA methylation levels in the DRD4 gene region finds associations with nearby SNPs, Behav. Brain Funct., 8, 31, 10.1186/1744-9081-8-31 Ishiguro, 2010, Brain cannabinoid CB2 receptor in schizophrenia, Biol. Psychiatry, 67, 974, 10.1016/j.biopsych.2009.09.024 Tong, 2013, Association of single-nucleotide polymorphisms in the cannabinoid receptor 2 gene with schizophrenia in the Han Chinese population, J. Mol. Neurosci., 51, 454, 10.1007/s12031-013-0062-0 Sadee, 2001, Genetic variations in human G protein-coupled receptors: implications for drug therapy, AAPS PharmSci., 3, 54, 10.1208/ps030322 Buscher, 2006, P2Y2 receptor polymorphisms and haplotypes in cystic fibrosis and their impact on Ca2+ influx, Pharmacogenet. Genomics, 16, 199, 10.1097/01.fpc.0000189798.11468.6a Wesselius, 2013, Association of P2Y(2) receptor SNPs with bone mineral density and osteoporosis risk in a cohort of Dutch fracture patients, Purinergic Signal., 9, 41, 10.1007/s11302-012-9326-3 Bodenmann, 2012, Polymorphisms of ADORA2A modulate psychomotor vigilance and the effects of caffeine on neurobehavioural performance and sleep EEG after sleep deprivation, Br. J. Pharmacol., 165, 1904, 10.1111/j.1476-5381.2011.01689.x Childs, 2008, Association between ADORA2A and DRD2 polymorphisms and caffeine-induced anxiety, Neuropsychopharmacology, 33, 2791, 10.1038/npp.2008.17 Freitag, 2010, Adenosine A(2A) receptor gene (ADORA2A) variants may increase autistic symptoms and anxiety in autism spectrum disorder, Eur. Child Adolesc. Psychiatry, 19, 67, 10.1007/s00787-009-0043-6 Rogers, 2010, Association of the anxiogenic and alerting effects of caffeine with ADORA2A and ADORA1 polymorphisms and habitual level of caffeine consumption, Neuropsychopharmacology, 35, 1973, 10.1038/npp.2010.71 Hohoff, 2010, Adenosine A(2A) receptor gene: evidence for association of risk variants with panic disorder and anxious personality, J. Psychiatr. Res., 44, 930, 10.1016/j.jpsychires.2010.02.006 Sie, 2009, Utility of lymphoblastoid cell lines, J. Neurosci. Res., 87, 1953, 10.1002/jnr.22000 Sugimoto, 2004, Steps involved in immortalization and tumorigenesis in human B-lymphoblastoid cell lines transformed by Epstein–Barr virus, Cancer Res., 64, 3361, 10.1158/0008-5472.CAN-04-0079 Hillger, 2015, Whole-cell biosensor for label-free detection of GPCR-mediated drug responses in personal cell lines, Biosens. Bioelectron., 74, 233, 10.1016/j.bios.2015.06.031 Morag, 2010, Human lymphoblastoid cell line panels: novel tools for assessing shared drug pathways, Pharmacogenomics, 11, 327, 10.2217/pgs.10.27 Yu, 2006, Real-time monitoring of morphological changes in living cells by electronic cell sensor arrays: an approach to study G protein-coupled receptors, Anal. Chem., 78, 35, 10.1021/ac051695v Label-Free, 2011, Label-free receptor assays, Drug Discov. Today Technol., 7, e5 Rocheville, 2013, Mining the potential of label-free biosensors for seven-transmembrane receptor drug discovery, Prog. Mol. Biol. Transl. Sci., 115, 123, 10.1016/B978-0-12-394587-7.00003-8 Willemsen, 2010, The Netherlands Twin Register biobank: a resource for genetic epidemiological studies, Twin Res. Hum. Genet., 13, 231, 10.1375/twin.13.3.231 Silventoinen, 2015, The CODA twins project: the cohort description of collaborative project of development of anthropometrical measures in twins to study macro-environmental variation in genetic and environmental effects on anthropometric traits, Twin Res. Hum. Genet., 18, 348, 10.1017/thg.2015.29 van Tilburg, 2002, 2,5′-Disubstituted adenosine derivatives: evaluation of selectivity and efficacy for the adenosine A(1), A(2A), and A(3) receptor, J. Med. Chem., 45, 420, 10.1021/jm010952v van Tilburg, 2003, 2,8-Disubstituted adenosine derivatives as partial agonists for the adenosine A2A receptor, Bioorg. Med. Chem., 11, 2183, 10.1016/S0968-0896(03)00123-8 Beukers, 2004, New, non-adenosine, high-potency agonists for the human adenosine A2B receptor with an improved selectivity profile compared to the reference agonist N-ethylcarboxamidoadenosine, J. Med. Chem., 47, 3707, 10.1021/jm049947s Miller, 1973, Release of infectious Epstein–Barr virus by transformed marmoset leukocytes, Proc. Natl. Acad. Sci. U.S.A., 70, 190, 10.1073/pnas.70.1.190 Engelstoft, 2013, Seven transmembrane G protein-coupled receptor repertoire of gastric ghrelin cells, Mol. Metab., 2, 376, 10.1016/j.molmet.2013.08.006 Guo, 2012, Functional efficacy of adenosine A(2)A receptor agonists is positively correlated to their receptor residence time, Br. J. Pharmacol., 166, 1846, 10.1111/j.1476-5381.2012.01897.x Cheng, 1973, Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction, Biochem. Pharmacol., 22, 3099, 10.1016/0006-2952(73)90196-2 Purcell, 2007, PLINK: a tool set for whole-genome association and population-based linkage analyses, Am. J. Hum. Genet., 81, 559, 10.1086/519795 S. Purcell, PLINK v1.07, <http://pngu.mgh.harvard.edu/purcell/plink/>. Scandroglio, 2010, Evaluation of cannabinoid receptor 2 and metabotropic glutamate receptor 1 functional responses using a cell impedance-based technology, J. Biomol. Screen., 15, 1238, 10.1177/1087057110375615 Sitkovsky, 2004, Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A2A receptors, Annu. Rev. Immunol., 22, 657, 10.1146/annurev.immunol.22.012703.104731 Desai, 2005, Adenosine A2A receptor stimulation increases angiogenesis by down-regulating production of the antiangiogenic matrix protein thrombospondin 1, Mol. Pharmacol., 67, 1406, 10.1124/mol.104.007807 Escudero, 2013, Impaired A2A adenosine receptor/nitric oxide/VEGF signaling pathway in fetal endothelium during late- and early-onset preeclampsia, Purinergic Signal., 9, 215, 10.1007/s11302-012-9341-4 Jacob, 2013, Purinergic signaling in inflammatory cells: P2 receptor expression, functional effects, and modulation of inflammatory responses, Purinergic Signal., 9, 285, 10.1007/s11302-013-9357-4 Lee, 2006, Expression of P2 receptors in human B cells and Epstein–Barr virus-transformed lymphoblastoid cell lines, BMC Immunol., 7, 22, 10.1186/1471-2172-7-22 Vincent, 2012, Genome-wide transcriptomic variations of human lymphoblastoid cell lines: insights from pairwise gene-expression correlations, Pharmacogenomics, 13, 1893, 10.2217/pgs.12.179 Yan, 2003, Adenosine receptor agonists: from basic medicinal chemistry to clinical development, Expert Opin. Emerg. Drugs, 8, 537, 10.1517/14728214.8.2.537 Eglen, 2011, Primary cells and stem cells in drug discovery: emerging tools for high-throughput screening, Assay Drug Dev. Technol., 9, 108, 10.1089/adt.2010.0305 Franca, 2015, Pharmacogenetics and induction/consolidation therapy toxicities in acute lymphoblastic leukemia patients treated with AIEOP-BFM ALL 2000 protocol, Pharmacogenomics J., 10.1038/tpj.2015.83 Schulte, 2000, Human adenosine A(1), A(2A), A(2B), and A(3) receptors expressed in Chinese hamster ovary cells all mediate the phosphorylation of extracellular-regulated kinase 1/2, Mol. Pharmacol., 58, 477, 10.1124/mol.58.3.477 Kase, 2003, Industry forum: progress in pursuit of therapeutic A2A antagonists: the adenosine A2A receptor selective antagonist KW6002: research and development toward a novel nondopaminergic therapy for Parkinson’s disease, Neurology, 61, S97, 10.1212/01.WNL.0000095219.22086.31